Dialogues from the Dais: CVD Risk Reduction in the Hypertriglyceridemic Patient

Multidisciplinary experts discuss complexities, challenges, and advances in the management of lipids to mitigate cardiovascular disease risk factors.

Live Broadcast
Information
December 10, 2020
07:00 PM - 08:30 PM CST
Dialogues from the Dais: CVD Risk Reduction in the Hypertriglyceridemic Patient

This live broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

Choose a format
Details
Presenters
Comments
  • Overview

    This highly interactive symposium will feature 5 leading experts addressing the complex interrelationship of cardiovascular disease risk factors. This symposium at the NLA 2020 Scientific Sessions is certain to be a “hot topic” with the recent release of REDUCE-IT and the continued recognition of lipid targets beyond LDL-C. This educational activity will provide the opportunity for the multidisciplinary faculty and symposium participants to work through complex issues that challenge healthcare providers who care for patients with elevated atherogenic cholesterol and triglycerides, many (or most) of whom have been suboptimally managed.

  • Program Schedule

    7:00 pm -7:10 pm

    Welcome and Opening Remarks
    Sergio Fazio, MD, PhD  Chair

    7:10 pm-7:25 pm

    What Have We Learned from the Omega-3 Trials?
    Michael Miller, MD

    7:25 pm-7:40 pm

    How Have the Guidelines Changed? Have They Helped?
    Eliot Brinton, MD, FAHA, FNLA

    7:40 pm-7:55 pm

    What Is the Role of Triglycerides in ASCVD?
    John R. Nelson, MD, FACC, FNLA, FASNC

    7:55 pm-8:10 pm

    What’s on the Horizon in Lipid Management?
    Sergio Fazio, MD, PhD  Chair

    8:10 pm-8:25 pm

    Challenging Cases for Discussion
    Margo B Minissian, PhD, ACNP

    8:25 pm-8:45 pm

    Questions & Answers
    Sergio Fazio, MD, PhD  Chair
    Eliot Brinton, MD, FAHA, FNLA
    Michael Miller, MD
    Margo B Minissian, PhD, ACNP
    John R. Nelson, MD, FACC, FNLA, FASNC

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that reduce atherosclerotic cardiovascular disease (ASCVD) events beyond statin therapy
    • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches to the management of care for patients with or at high risk of ASCVD events
    • Discuss strategies to improve the knowledge, skills, or performance of the healthcare team

  • Target Audience

    This activity is designed to meet the educational needs of lipid specialists, diabetologists, clinical endocrinologists, internal medicine and primary care physicians, cardiologists, diabetes educators, and others who diagnose and treat patients at increased residual risk for ASCVD worldwide.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Details
Presenters
Comments
  • Overview

    This highly interactive symposium will feature 5 leading experts addressing the complex interrelationship of cardiovascular disease risk factors. This symposium at the NLA 2020 Scientific Sessions is certain to be a “hot topic” with the recent release of REDUCE-IT and the continued recognition of lipid targets beyond LDL-C. This educational activity will provide the opportunity for the multidisciplinary faculty and symposium participants to work through complex issues that challenge healthcare providers who care for patients with elevated atherogenic cholesterol and triglycerides, many (or most) of whom have been suboptimally managed.

  • Program Schedule

    7:00 pm -7:10 pm

    Welcome and Opening Remarks
    Sergio Fazio, MD, PhD  Chair

    7:10 pm-7:25 pm

    What Have We Learned from the Omega-3 Trials?
    Michael Miller, MD

    7:25 pm-7:40 pm

    How Have the Guidelines Changed? Have They Helped?
    Eliot Brinton, MD, FAHA, FNLA

    7:40 pm-7:55 pm

    What Is the Role of Triglycerides in ASCVD?
    John R. Nelson, MD, FACC, FNLA, FASNC

    7:55 pm-8:10 pm

    What’s on the Horizon in Lipid Management?
    Sergio Fazio, MD, PhD  Chair

    8:10 pm-8:25 pm

    Challenging Cases for Discussion
    Margo B Minissian, PhD, ACNP

    8:25 pm-8:45 pm

    Questions & Answers
    Sergio Fazio, MD, PhD  Chair
    Eliot Brinton, MD, FAHA, FNLA
    Michael Miller, MD
    Margo B Minissian, PhD, ACNP
    John R. Nelson, MD, FACC, FNLA, FASNC

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that reduce atherosclerotic cardiovascular disease (ASCVD) events beyond statin therapy
    • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches to the management of care for patients with or at high risk of ASCVD events
    • Discuss strategies to improve the knowledge, skills, or performance of the healthcare team

  • Target Audience

    This activity is designed to meet the educational needs of lipid specialists, diabetologists, clinical endocrinologists, internal medicine and primary care physicians, cardiologists, diabetes educators, and others who diagnose and treat patients at increased residual risk for ASCVD worldwide.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free